Alnylam Pharmaceuticals | ALNY - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 3.98M 22.34M 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Amgen USD 1.51B 2.41B 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Moderna USD -1.33B 535M 2026-03
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novartis USD 3.84B 1.33B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.53B 696.6M 2026-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sanofi EUR 2B 3.16B 2026-03
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Takeda JPY 162.72B 215.2B 2026-06
Tectonic Therapeutic USD -18.97M 63K 2025-12
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03
Xencor USD -128.64M 124.37M 2026-03